ArticleThoracic cancer2026
The Predictive Value of Neutrophil-To-Lymphocyte Ratio (NLR) for Response to Neoadjuvant Immunochemotherapy in Resectable IIA-IIIB Non-Small Cell Lung Cancer in Real-World Practice.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline Neutrophil-to-Lymphocyte Ratio and Two-Year Incident Distant Metastasis in Stage I-III Lung Cancer: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveA significant clinical challenge remains the identification of non-small cell lung cancer (NSCLC) patients who will derive maximum benefit from neoadjuvant immunochemotherapy. The neutrophil-to-lymphocyte ratio (NLR) may offer critical insights into the host's capacity to mount an effective anti-tumor response.
methodsThis retrospective study consecutively included patients with stage IIA-IIIB NSCLC who received 2-4 cycles of platinum-based immunochemotherapy prior to planned resection at the Department of Thoracic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine from 2017 to 2022.
resultsA total of 317 patients were included in our study and divided into two groups according to the median baseline NLR (3.27) of the whole population: low NLR (< 3.27) group (160 patients) and high NLR (≥ 3.27) group (157 patients). The rate of MPR in the low NLR group was significantly higher than that in the high NLR group (58.3% vs. 38.5%, p = 0.008). The median PFS in the low NLR group was not reached and 21.6 months (95% confidence interval [CI], 16.9 to 26.3) in the high NLR group (hazard ratio [HR] for disease progression, disease recurrence, or death, 0.431; 95% CI, 0.312 to 0.594; p < 0.001). The median OS in the low NLR group was not reached and 33.2 months (95% CI, 18.8 to 47.6) in the high NLR group (HR for death, 0.416; 95% CI, 0.295 to 0.586; p < 0.001).
conclusionsA low pre-treatment NLR is a predictive marker of enhanced pathological response and improved survival outcomes in IIA-IIIB NSCLC patients undergoing neoadjuvant immunochemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.